Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPC Trial 23: Adjuvant Bicalutamide in Early Prostate Cancer
NCT00657904Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 1995
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of bicalutamide in prostate cancer (PCa), sponsored by AstraZeneca. Started Aug 1995; status: completed.
02
Drugs
bicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00657904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657904.